Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

MedTech sector outlook for 2025: RBC

admin by admin
December 21, 2024
in Stock
0
MedTech sector outlook for 2025: RBC
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

Investing.com — RBC Capital Markets is feeling bullish about the MedTech sector heading into 2025, noting a robust environment driven by innovation, favorable demographics, and a pro-business policy landscape under the Trump administration.

The firm highlights significant opportunities across its coverage universe, from large-cap leaders to emerging mid-cap innovators.

According to RBC, 2025 will be a “catalyst-rich” year for the sector. Large-cap names like Intuitive Surgical Inc (NASDAQ:ISRG) and Boston Scientific Corp (NYSE:BSX) are poised to deliver a standout performance.

ISRG remains a top pick, with its anticipated mid-year launch of the da Vinci (EPA:SGEF) 5 system representing “a major potential catalyst,” according to RBC analysts.

The company’s leadership in surgical robotics, a high-margin and underpenetrated market, positions it for double-digit revenue and earnings per share (EPS) growth.

Similarly, BSX remains uniquely positioned in the cardiovascular and electrophysiology markets, with strong catalysts expected to unfold, including advancements in pulsed field ablation (PFA) and Watchman devices.

“We see BSX as a premier large-cap company poised to deliver double-digit sales and EPS growth in 2025 that is top-tier in MedTech,” analysts led by Shagun Singh said.

In addition to these industry leaders, analysts also point to opportunities in dislocated large-cap names like DexCom Inc (NASDAQ:DXCM), Medtronic PLC (NYSE:MDT), and Edwards Lifesciences Corp (NYSE:EW).

DXCM, described as “the most dislocated name” in RBC’s large-cap coverage, is poised for a turnaround, driven by innovations such as the 15-day G7 sensor.

Meanwhile, MDT offers compelling relative value as it navigates a business turnaround, with renal denervation (RDN) emerging as a key catalyst.

EW, following a reset in investor expectations, is expected to capitalize on growth in transcatheter valve therapies (TAVR) and new interventional categories.

In the mid-cap space, RBC highlights Inspire Medical Systems Inc (NYSE:INSP) and Globus Medical (NYSE:GMED) as standout names.

INSP is leveraging its first-mover advantage in the obstructive sleep apnea market, with next-generation devices and increasing adoption driving significant upside potential.

GMED, known for its strong execution, is positioned for growth as it integrates Nuvasive and continues to innovate in orthopedic and neurosurgical robotics.

“GMED is a top SMID-cap pick for 2025 as return to historical growth/margin profile aided by best-in-class execution appears poised to drive upside,” analysts said.

Speaking more broadly, RBC notes that sector-wide tailwinds, including aging demographics, a shift to more efficient care settings, and the integration of AI and digital solutions, will underpin long-term growth. The firm emphasizes the impact of innovation, particularly in underpenetrated markets such as robotic-assisted surgery, diabetes care, and vascular interventions.

The Trump administration’s policies are seen as broadly favorable for MedTech, with potential corporate tax reductions and a pro-innovation regulatory stance likely to benefit the sector.

Historically, the RBC Large-Cap MedTech Index has outperformed the broader market by an average of 16% during the first year of new presidential terms.

“Overall, we are bullish on the Medical (TASE:PMCN) Supplies & Devices sector in 2025 and like its relative healthcare positioning, and see factors supporting a multi-year runway ahead,” the investment bank concluded.

This post appeared first on investing.com

Previous Post

Biden mulls exempting Mexico from imported solar gear tariffs, Bloomberg News reports

Next Post

GLP-1: Barclays on why 2025 could be an inflection point

admin

admin

Next Post
GLP-1: Barclays on why 2025 could be an inflection point

GLP-1: Barclays on why 2025 could be an inflection point

Trending News

ERN price soars 125% as Binance backs Ethernity Chain’s rebrand

ERN price soars 125% as Binance backs Ethernity Chain’s rebrand

February 28, 2025
DJT stock jumps 10% after Trump rules out selling stake in Truth Social operator

DJT stock jumps 10% after Trump rules out selling stake in Truth Social operator

November 9, 2024
US equity funds attract inflows for fourth successive week

US equity funds attract inflows for fourth successive week

November 29, 2024
Subscribe to Insightful Word


    Recent News

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    June 6, 2025
    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    June 6, 2025
    Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    June 6, 2025
    Starlink reportedly secures key licence in India, moves closer to launching services

    Starlink reportedly secures key licence in India, moves closer to launching services

    June 6, 2025

    Recent News

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll

    June 6, 2025
    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more

    June 6, 2025

    Latest News

    • China’s May export growth seen slowing to 5.0% amid trade uncertainty: Reuters poll
    • FTSE 100 Index shares of 2025: Rolls-Royce, Fresnillo, BAE, and more
    • Asian stocks end mixed: Hang Seng snaps winning streak, Nikkei jumps 0.5%

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.